8-K current report · filed Nov 2, 2026

10x Genomics, Inc. (TXG) 8-K Current Report: November 2, 2026

Item 5.02TXG overview

Short answer

10x Genomics, Inc. (TXG) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board additions: Ansuman Satpathy and Joseph Gilliam appointed Class III directors through 2028 annual meeting.

10x Genomics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board additions: Ansuman Satpathy and Joseph Gilliam appointed Class III directors through 2028 annual meeting
  • Satpathy adds genomics, immunology, AI-enabled drug discovery and biotech venture expertise
  • Gilliam adds public-company operating, healthcare investment banking, accounting and audit committee experience
  • Director compensation: $60,000 annual cash retainer, $400,000 initial RSU grant and $215,000 annual RSU grant
  • Gilliam appointed Audit Committee Chair with additional $25,000 annual retainer, strengthening financial oversight

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other 10x Genomics, Inc. 8-K filings

Get the next TXG 8-K as it lands

Follow TXG for push alerts, or ask the research agent what this filing means.